SREBF1 and neoplasm: These findings indirectly suggested that SREBP1 reversed the inhibitory impact of CLDN6 on RAS palmitoylation in tumor tissues, while the palmitoylation inhibitor 2BP collaborated with CLDN6 to suppress RAS palmitoylation.